Crispr Therapeutics AG vs Essex Property Trust, Inc. — how do they compare? Crispr Therapeutics AG trades at $53.88 (market cap $5.23B), while Essex Property Trust, Inc. trades at $282.11 (market cap $18.15B). The key difference: Essex Property Trust, Inc. is far larger — about 3.5× Crispr Therapeutics AG's market cap, and Essex Property Trust, Inc. pays a 3.93% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | ESS | |
|---|---|---|
Market Cap | $5.23B | $18.15B |
Sector | Health | Real Estate |
52-Week High | $76.78 | $298.33 |
52-Week Low | $44.34 | $239.61 |
Enterprise Value | $3.65B | $24.75B |
Dividend Yield | — | 3.93% |
Trailing returns across standard periods
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →